Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$27.5 - $37.92 $287,375 - $396,264
-10,450 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$34.44 - $43.75 $372,813 - $473,593
-10,825 Reduced 50.88%
10,450 $564,000
Q2 2020

Aug 14, 2020

BUY
$27.12 - $45.97 $165,242 - $280,095
6,093 Added 40.13%
21,275 $1.3 Million
Q1 2020

May 14, 2020

SELL
$26.16 - $63.5 $3,348 - $8,128
-128 Reduced 0.84%
15,182 $698,000
Q4 2019

Feb 13, 2020

SELL
$46.96 - $61.67 $1.05 Million - $1.38 Million
-22,349 Reduced 59.35%
15,310 $1.34 Million
Q3 2019

Nov 13, 2019

SELL
$59.47 - $93.1 $1.47 Million - $2.3 Million
-24,652 Reduced 39.56%
37,659 $3.47 Million
Q2 2019

Aug 08, 2019

SELL
$75.84 - $105.21 $1.93 Million - $2.68 Million
-25,469 Reduced 29.01%
62,311 $7.93 Million
Q1 2019

May 13, 2019

SELL
$64.44 - $104.11 $269,745 - $435,804
-4,186 Reduced 4.55%
87,780 $13.8 Million
Q4 2018

Feb 14, 2019

SELL
$59.1 - $93.26 $550,161 - $868,157
-9,309 Reduced 9.19%
91,966 $9.08 Million
Q3 2018

Nov 13, 2018

BUY
$88.86 - $117.49 $198,246 - $262,120
2,231 Added 2.25%
101,275 $14.8 Million
Q2 2018

Aug 13, 2018

BUY
$99.64 - $127.59 $3.6 Million - $4.61 Million
36,155 Added 57.49%
99,044 $15.5 Million
Q1 2018

May 14, 2018

BUY
$105.8 - $150.94 $1.51 Million - $2.16 Million
14,298 Added 29.43%
62,889 $10.7 Million
Q4 2017

Feb 13, 2018

BUY
$81.25 - $130.7 $2.32 Million - $3.73 Million
28,513 Added 142.01%
48,591 $8.65 Million
Q3 2017

Nov 13, 2017

SELL
$57.74 - $91.42 $73,387 - $116,194
-1,271 Reduced 5.95%
20,078 $2.76 Million
Q2 2017

Aug 14, 2017

BUY
N/A
690 Added 3.34%
21,349 $2.3 Million
Q1 2017

Apr 17, 2019

SELL
N/A
-72,078 Reduced 77.72%
20,659 $1.88 Million
Q4 2016

Apr 17, 2019

SELL
N/A
-20,352 Reduced 18.0%
92,737 $5.72 Million
Q3 2016

Apr 17, 2019

BUY
N/A
113,089
113,089 $7.65 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $23.1M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.